Nucala Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of severe eosinophilic asthma, increased recognition of eosinophilic disorders, expansion of biologic treatment guidelines, improved diagnostic testing for eosinophil levels, growing specialist prescribing practices.

The growth in the forecast period can be attributed to increasing expansion into additional eosinophilic indications, rising demand for personalized respiratory biologics, advancements in monoclonal antibody engineering, broader global reimbursement coverage, increased home-based administration adoption. Major trends in the forecast period include increasing adoption of targeted biologic asthma therapies, growing use of IL-5 inhibitors in chronic conditions, expansion of precision medicine approaches in respiratory care, rising focus on long-term disease control, enhanced patient stratification practices.

The increasing prevalence of asthma is expected to drive the growth of the Nucala market going forward. Asthma is a chronic respiratory condition characterized by airway inflammation and narrowing, resulting in symptoms such as wheezing, coughing, chest tightness, and shortness of breath, often triggered by allergens or physical activity. The rising prevalence of asthma is attributed to factors such as environmental pollution, exposure to allergens, urbanization, lifestyle changes, and genetic predisposition. Nucala works by targeting and inhibiting interleukin-5 (IL-5), a protein involved in the growth and activation of eosinophils, which are white blood cells that contribute to airway inflammation in asthma, thereby reducing symptoms and the frequency of asthma exacerbations. For instance, in February 2023, NHS England reported that 5.4 million people in the UK receive asthma treatment, with around 160,000 new diagnoses annually, and work-related asthma accounting for 9-15% of adult-onset cases. Therefore, the increasing prevalence of asthma is driving growth in the Nucala market.

The increasing prevalence of eosinophilic disorders is expected to propel the growth of the Nucala market going forward. Eosinophilic disorders are medical conditions marked by the overproduction and accumulation of eosinophils in various tissues, leading to inflammation and potential tissue damage. The rising prevalence of these disorders is linked to factors such as increased environmental allergens, changes in diet, genetic predispositions, and heightened awareness resulting in improved diagnostic rates. Nucala (mepolizumab) treats eosinophilic disorders by inhibiting interleukin-5 (IL-5), a cytokine responsible for eosinophil growth and survival, thereby lowering eosinophil levels and alleviating related symptoms. For instance, in December 2023, PubMed reported a global pooled incidence and prevalence of eosinophilic esophagitis (EoE) at 5.31 cases per 100,000 inhabitant-years. Therefore, the increasing prevalence of eosinophilic disorders is driving growth in the Nucala market.

Major companies operating in the Nucala market are focusing on developing innovative solutions, such as ready-to-use injectable formulations, to enhance patient convenience and improve treatment adherence. Ready-to-use injectables are pre-prepared pharmaceutical products requiring no further dilution or mixing before administration. For instance, in May 2025, GlaxoSmithKline Plc received US FDA approval for Nucala (mepolizumab) for the treatment of adults with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This indication expansion allows targeted therapy for COPD patients with high unmet needs, supported by positive results from the MATINEE and METREX Phase III trials.

Major companies operating in the nucala market are GlaxoSmithKline plc.

North America was the largest region in the nucala market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucala market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nucala market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the nucala market by increasing costs related to imported monoclonal antibody production inputs, bioprocessing equipment, cold-chain transportation, and specialty packaging components. North America and Europe are most affected due to complex biologics supply chains, while Asia-Pacific faces higher import costs for finished biologic products. These tariffs place upward pressure on treatment pricing and healthcare budgets. At the same time, they are encouraging regional biologics manufacturing expansion, localized fill-finish capacity, and long-term investments in domestic biologic production infrastructure.

The nucala market research report is one of a series of new reports that provides nucala market statistics, including nucala industry global market size, regional shares, competitors with a nucala market share, detailed nucala market segments, market trends and opportunities, and any further data you may need to thrive in the nucala industry. This nucala market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nucala (mepolizumab) is a monoclonal antibody biologic therapy that targets and inhibits interleukin-5 (IL-5), a cytokine critical for the growth, activation, and survival of eosinophils. By reducing eosinophilic inflammation, it helps manage symptoms and decrease the frequency of exacerbations in patients with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and other eosinophil-driven conditions.

The primary indications for Nucala include severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), chronic obstructive pulmonary disease (COPD), and other eosinophilic disorders. Severe asthma is a difficult-to-control form of asthma that requires higher medication doses and is characterized by persistent symptoms such as wheezing and breathlessness despite standard treatments. Nucala is distributed through direct sales, retail pharmacies, and online pharmacies and is used in hospitals, clinics, and home care settings.

The nucala market consists of sales of nucala 100mg injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.